Results 321 to 330 of about 2,608,517 (407)
Fibrosing Mediastinitis and Complete Right Pulmonary Artery Occlusion. [PDF]
Ufuk F.
europepmc +1 more source
Manganese Neurotoxicity and Familial Disorders of Manganese Transport
ABSTRACT Manganese is the 12th most common element in the Earth's crust and is an essential industrial component. Biologically, this metal plays an important role as a constituent of numerous enzymes. While manganese is required for normal biochemical and physiological processes, manganese excess can lead to significant toxicity, particularly to the ...
Sidney M. Gospe Jr.
wiley +1 more source
Association Between Bicuspid Aortic Valve and Main Pulmonary Artery Dilation in Adult Patients. [PDF]
Hay AV+7 more
europepmc +1 more source
Abstract Bexicaserin (LP352) is a selective superagonist of the 5‐hydroxytryptamine 2C (5‐HT2C) receptor currently in development for the treatment of seizures that arise from developmental and epileptic encephalopathies. This phase 1, double‐blind, placebo‐controlled multiple ascending dose (MAD) study assessed the safety, tolerability, and ...
Jonathan Williams+7 more
wiley +1 more source
A novel iron bioresorbable scaffold: a potential strategy for pulmonary artery stenosis. [PDF]
Qin L+15 more
europepmc +1 more source
Prasugrel is recommended for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI). However, East Asians exhibit a stronger antiplatelet response, raising concerns about bleeding risks with standard dosing. This retrospective cohort study evaluated the real‐world effectiveness and safety of reduced‐dose prasugrel in
Li‐Wen Huang+6 more
wiley +1 more source
Point-of-Care Ultrasound for Guiding Pulmonary Artery Catheter Placement. [PDF]
Su E, Flores S.
europepmc +1 more source
Expediting Drug Development in Japan: A PMDA Perspective
Review time for a new drug in Japan has shortened dramatically since the establishment of the Pharmaceuticals and Medical Devices Agency (PMDA). Nonetheless, Japan faces a new challenge so‐called “Drug Loss”, which means that new drugs approved overseas have not yet been developed in Japan or that development is delayed. In this manuscript, we describe
Yoichi Kohno+8 more
wiley +1 more source